Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Target |
Action inhibitors |
Mechanism KRAS inhibitors(GTPase KRas inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
KRAS mutation-related tumors | Preclinical | United States | 23 Dec 2019 | |
KRAS mutation-related tumors | Preclinical | United States | 23 Dec 2019 |